Last updated: February 15, 2026
Product Overview
NDC 70512-0850 refers to Repatha (evolocumab), a monoclonal antibody developed by Amgen for lowering LDL cholesterol. The drug is approved for familial hypercholesterolemia, clinical atherosclerotic cardiovascular disease, and other hyperlipidemia conditions. It entered the market in 2015 and competes directly with other PCSK9 inhibitors like Praluent (alirocumab).
Market Size and Demand Drivers
- The global hypercholesterolemia treatment market was valued at approximately USD 11.3 billion in 2022.
- CAGR projected at 6.2% from 2023 to 2028, driven by increasing cardiovascular disease prevalence, aging populations, and a shift toward high-intensity lipid management.
- Key patient populations include familial hypercholesterolemia (estimated at 290,000 globally) and statin-intolerant patients.
Market Penetration
Repatha’s market share reflects strong adoption within specialty cardiology clinics but faces limitations due to high cost and administration route (subcutaneous injection).
- Estimated U.S. sales in 2022: USD 1.4 billion.
- Expected to reach USD 2.5 billion by 2028, based on current growth trends and expanding indications.
Competitive Landscape
- Praluent (alirocumab) is the primary competitor, priced marginally lower.
- Other emerging PCSK9 inhibitors in development could influence future market dynamics.
- Biosimilar introduction remains unlikely within the next five years due to complexity and patent protections.
Pricing Overview and Projections
- Current Price Point: Wholesale Acquisition Cost (WAC) is approximately USD 5,850 per month for Repatha.
- Patient Access Program: Insurance reimbursement and patient assistance programs mitigate out-of-pocket costs, but high list prices hinder broader adoption.
- Market Pressure: Announcements of price reductions or biosimilar alternatives can influence pricing strategies.
Price Trends and Projections (2023-2028)
| Year |
Approximate WAC (USD/month) |
Expected Market Reaction |
| 2023 |
USD 5,850 |
Stable; high-cost perception persists, but reimbursement limits patient out-of-pocket |
| 2024 |
USD 5,750 |
Slight pressure from payers; increased competition from biosimilars unlikely |
| 2025 |
USD 5,500 |
Potential discounts in managed-care contracts; volume-based pricing increases |
| 2026 |
USD 5,250 |
Biosimilar emergence might influence list prices; less significant impact present |
| 2027 |
USD 5,000 |
Slight reduction anticipated; market saturation limiting further decreases |
| 2028 |
USD 4,850 |
Cost pressures and broader generic biosimilar availability may exert downward pressure |
Pricing Sensitivity Factors
- Reimbursement policies.
- Patent litigation and biosimilar approvals.
- Physician prescribing habits.
- Patient adoption rates.
Key Challenges & Opportunities
- Pricing pressure stems from background of increasing competition, biosimilar entry, and payer cost containment.
- Opportunities include expanding indications, entering emerging markets, and leveraging biosimilar/portfolio strategies.
Regulatory and Policy Impact
- Price negotiations facilitated by CMS and private payers influence net pricing.
- Policies supporting biosimilar approval and substitution could lead to significant price reductions post-2024.
Summary
Repatha’s market outlook suggests stable demand within targeted high-risk populations. Prices are expected to gradually decline, primarily influenced by biosimilar competition and payer negotiations. Continued expansion into broader indications and international markets could sustain growth despite pricing pressures.
Key Takeaways
- Repatha's 2022 US sales reached USD 1.4 billion; global potential exceeds USD 10 billion.
- Current list price is approximately USD 5,850/month.
- Market growth driven by rising cardiovascular disease prevalence; CAGR near 6.2% (2023-2028).
- Price projections indicate gradual reduction to roughly USD 4,850/month by 2028.
- Biosimilar introduction and reimbursement policies remain primary drivers of future price movements.
FAQs
1. What is the primary competition for NDC 70512-0850?
Praluent (alirocumab) is the main competitor, with similar efficacy but a slightly lower price point.
2. How does biosimilar entry affect the market?
Biosimilars can exert downward pressure on prices, especially after patent expiry (~2026-2028), potentially reducing list prices by up to 30-50%.
3. What are the main factors influencing Repatha's price?
Reimbursement policies, patent status, biosimilar availability, and market penetration strategies.
4. How does the global market compare?
Emerging markets offer growth potential but face pricing and reimbursement challenges. Established markets dominate revenue streams.
5. What strategies could Amphend pursue to maintain competitiveness?
Innovate indications, reduce list prices, expand biosimilar collaborations, or develop new delivery systems.
Sources
- IQVIA, 2022.
- Amgen annual report, 2022.
- FDA approval documents for evolocumab.
- Deloitte, 2023.
- Health economics and outcomes research reports, 2023.
[1] IQVIA, "Pharmaceutical Market Reports," 2022.
[2] Amgen, "Repatha Product Information," 2022.
[3] U.S. Food & Drug Administration, "Approval Details," 2015.
[4] Deloitte Insights, "Biopharma Pricing Trends," 2023.
[5] MarketWatch, "PCSK9 Inhibitors Market Outlook," 2023.
